Cargando…

The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers

The dual tyrosine kinase (EGFR/HER2) inhibitor lapatinib is currently used to clinically treat HER2-positive breast cancer. However, a majority of patients do not respond to lapatinib therapy within 6 months. Therefore, potentiating the anti-tumor effect of lapatinib by combination treatment has a g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Ziyin, Yang, Yan, Wu, He, Chen, Yongye, Jia, Hao, Zhu, Lei, He, Runjia, Jin, Yibo, Zhou, Bei, Ge, Chunpo, Sun, Yanxia, Yang, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449760/ https://www.ncbi.nlm.nih.gov/pubmed/36090218 http://dx.doi.org/10.1016/j.heliyon.2022.e10410

Ejemplares similares

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
por: Yang, Yun, et al.
Publicado: (2020)

Brusatol, an NRF2 inhibitor for future cancer therapeutic
por: Cai, Sabrina J., et al.
Publicado: (2019)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Brusatol
por: Hu, Shu-Zhi, et al.
Publicado: (2012)

Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway
por: Xiang, Yukai, et al.
Publicado: (2018)

Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells
por: Chen, Hai-Ming, et al.
Publicado: (2018)

The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
por: Evans, Jonathan P., et al.
Publicado: (2018)

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib
por: Kankia, Ibrahim H., et al.
Publicado: (2017)

UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response
por: Wang, Mei, et al.
Publicado: (2018)

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
por: Evans, Jonathan P., et al.
Publicado: (2019)

Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2
por: Olayanju, Adedamola, et al.
Publicado: (2015)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy
por: Yang, Yun, et al.
Publicado: (2023)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma
por: Lee, Jong Hyun, et al.
Publicado: (2019)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
por: Dratkiewicz, Ewelina, et al.
Publicado: (2018)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells
por: OKITA, RIKI, et al.
Publicado: (2015)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumor Effect in Breast Cancer by Targeting Nrf2 Signaling Pathway
por: Li, Jing, et al.
Publicado: (2023)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
por: Park, Youngmok, et al.
Publicado: (2016)

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
por: Christenson, Jessica L., et al.
Publicado: (2015)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2015)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo
por: Siddique, Abu Bakar, et al.
Publicado: (2019)

The toxic effects and possible mechanisms of Brusatol on mouse oocytes
por: Ma, Rujun, et al.
Publicado: (2017)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_keks8v0v0e1f87af24h99sliv1